Riskpilot← Back to searchSign inGet full accessImmuvent AB
ABActiveOrg 5567522189Sysslomansgatan 47 FGeneral medical practice activities · NACE 8621Est. 20080 employees
Revenue 2025
SEK 0
EBITDA margin
—
+30% vs 2024
Equity ratio
91.8%
Financial strength
Net profit 2025
SEK -33K
+98% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -18K | +30% |
| Net profit | SEK -33K | +98% |
| Total assets | SEK 365K | -11% |
| Equity | SEK 335K | -9% |
| Employees | 0 | — |
Legal name
Immuvent AB
Org number
5567522189
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
21 februari 2008
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva konsultationer inom medicin, friskvård samt försäkringsfrågor. Bolaget ska även bedriva förvaltning av värdepapper och fastigheter.
Address
Sysslomansgatan 47 F
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −53 | −25 | −27 | −26 | −18 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −53 | −25 | −27 | −26 | −18 |
| Net financials | −558 | 148 | 55 | −1 653 | −15 |
| Profit before tax | 381 | 123 | 28 | −1 678 | −33 |
| Tax | −0 | — | — | −38 | — |
| Net profit | 381 | 123 | 28 | −1 716 | −33 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 669 | 2 452 | 2 285 | 411 | 365 |
| Equity | 2 661 | 2 443 | 2 280 | 368 | 335 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 8 | 8 | 5 | 43 | 30 |
| Total debt | 8 | 8 | 5 | 43 | 30 |
EBITDA margin
-1799600.0%
This company
15.8%
Market median
-11389973% vs market
20212025
Equity ratio
91.8%
This company
38.2%
Market median
+140% vs market
20212025
Return on equity
-9.9%
This company
18.4%
Market median
-154% vs market
20212025
Net profit margin
-3310800.0%
This company
8.1%
Market median
-40874174% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.09×
This company
0.62×
Market median
+85% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Immuvent AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Henrik Tötterman | Board of Directors | 0 companies |
| Auli Kristiina Tötterman | Deputy Board Member | 0 companies |